ПРИМЕНЕНИЕ ДЛИТЕЛЬНО ДЕЙСТВУЮЩИХ ДИГИДРОПИРИДИНОВЫХ АНТАГОНИСТОВ КАЛЬЦИЯ ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК: ВОЗМОЖНОСТИ И ПЕРСПЕКТИВЫ
- Авторы: Фомин ВВ1, Гирина СС1, Fomin VV2, Girina SS2
-
Учреждения:
- Кафедра терапии и профболезней ММА им. И.М. Сеченова, Москва
- Выпуск: № 2 (2010)
- Страницы: 72-76
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2075-3594/article/view/245891
- ID: 245891
Цитировать
Полный текст
Аннотация
Представлено обоснование применения длительно действующих дигидопиридиновых антагонистов кальция, в частности, фелодипина, для лечения и профилактики хронической болезни почек
Ключевые слова
Об авторах
В В Фомин
Кафедра терапии и профболезней ММА им. И.М. Сеченова, МоскваКафедра терапии и профболезней ММА им. И.М. Сеченова, Москва
С С Гирина
Кафедра терапии и профболезней ММА им. И.М. Сеченова, МоскваКафедра терапии и профболезней ММА им. И.М. Сеченова, Москва
V V Fomin
S S Girina
Список литературы
- Coresh J., Selvin E., Stevens L.A. et al. Prevalence of chronic kidney disease in the United States. J.A.M.A. 2007; 298(17): 2038-2047
- Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50 - 55
- Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардио-ренальный континуум: патогенетические основы превентивной нефрологии. Нефрология. 2005; 9(3): 7 - 12
- Кутырина И.М., Мартынов СА., Швецов М.Ю. и др. Артериальная гипертония при хроническом гломерулонефрите: частота выявления и эффективность лечения. Тер. арх. 2004; 9: 10 - 15
- Siamopoulos K.C., Kalaitzidis R.G. Inhibition of the renin-angiotensin system and chronic kidney disease. Int. Urol. Nephrol. 2008; 40(4): 1015-1025
- Peralta C.A., Hicks L.S., Chertow G.M. et al. Control of hypertension in adults with chronic kidney disease in the United States. Hypertension. 2005; 45(6): 1119-1124
- Plantinga L.C., Miller E.R. 3rd, Stevens L.A. et al.; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. Blood pressure control among persons without and with chronic kidney disease: US trends and risk factors 1999-2006. Hypertension. 2009; 54(1): 47-56
- Duru O.K., Li S., Jurkovitz C. et al. Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP). Am. J. Kidney Dis. 2008; 51(2): 192-198
- Российское Медицинское Общество по Артериальной Гипертонии - Всероссийское Научное Общество Кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр.). М., 2008
- Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. Сердце. 2005; 4(3): 120 - 126
- Jameson K., Weber M.A., Bakris G.L. et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417 - 2428
- Ruggenenti P., Schieppati A., Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001; 357: 1601 - 1608
- The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997; 349(9069): 1857-1863
- Agodoa L.Y., Appel L., Bakris G.L. et al.; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. J.A.M.A. 2001; 285(21): 2719-2728
- Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001; 345: 851 - 860
- Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118): 1755-1762
- Ruilope L.M., Salvetti A., Jamerson K. et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J. Am. Soc. Nephrol. 2001; 12(2): 218-225
- Staessen J.A., Fagard R., Thijs L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757 - 764
- Voyaki S.M., Staessen J.A., Thijs L. et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. J. Hypertens. 2001; 19: 511 - 519
- Gerber L.M., Shmukler C., Alderman M.H. Differences in urinary albumin excretion rate between normotensive and hypertensive, white and nonwhite subjects. Arch. Intern. Med. 1992; 152: 373 - 377
- Cirillo M., Stellato D., Laurenzi M. et al. Pulse pressure and isolated systolic hypertension: association with microalbuminuria. The GUBBIO Study Collaborative Research Group. Kidney Int. 2000; 58(3): 1211-1218
- Gerdts E., Papademetriou V., Palmieri V. et al.; Losartan Intervention For End (LIFE) point reduction in hypertension study. Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). Am. J. Cardiol. 2002; 89(4): 399-402
- Klag M.J., Whelton P.K., Randall B.L. et al. End-stage renal disease in African-American and white men: 16-year MRFIT findings. J.A.M.A. 1997; 277: 1293 - 1298
- Domrongkitchaiporn S., Sritara P., Kitiyakara C. et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J. Am. Soc. Nephrol. 2005; 16: 791 - 799
- Vikse B.E., Aasarød K., Bostad L., Iversen B.M. Clinical prognostic factors in biopsy-proven benign nephrosclerosis. Nephrol. Dial. Transplant. 2003; 18(3): 517-523
- Fesler P., Ribstein J., du Cailar G., Mimran A. Determinants of cardiorenal damage progression in normotensive and never-treated hypertensive subjects. Kidney Int. 2005; 67(5): 1974-1979
- Mimran A. Consequences of elevated pulse pressure on renal function. J. Hypertens. Suppl. 2006; 24(3): S3-S7
- Fesler P., Safar M.E., du Cailar G. et al. Pulse pressure is an independent determinant of renal function decline during treatment of essential hypertension. J. Hypertens. 2007; 25(9): 1915-1920
- Verhave J.C., Fesler P., du Cailar G. et al. Elevated pulse pressure is associated with low renal function in elderly patients with isolated systolic hypertension. Hypertension. 2005; 45(4): 586-591
- Liu L., Zhang Y., Liu G.; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J. Hypertens. 2005; 23(12): 2157-2172
- Dougall H.T., McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf. 1996; 15(2): 91-106
- Schaefer R.M., Aldons P.M., Burgess E.D. et al. Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. Int. J. Clin. Pract. 1998; 52(6): 381-386
- Bicchi M., Vedovini G., Cappelli R. et al. Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension. Angiology. 1998; 49(5): 373-380
- Herlitz H., Harris K., Risler T. et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol. Dial. Transplant. 2001; 16(11): 2158-2165
- Cattran D.C., Alexopoulos E., Heering P. et al. Cyclosporin in idiopathic glomerular disease associated with the nephritic syndrome: workshop recommendations. Kidney Int. 2007; 72(12): 1429 - 1447
- Sørensen S.S., Skovbon H., Eiskjaer H. et al. Effect of felodipine on renal haemodynamics and tubular sodium handling in cyclosporin-treated renal transplant recipients. Nephrol. Dial. Transplant. 1992; 7(1): 69-78
- Pedersen E.B., Madsen J.K., Sørensen S.S., Zachariae H. Improvement in renal function by felodipine during cyclosporine treatment in acute and short-term studies. Kidney Int. Suppl. 1996; 55: S94-S96
- Madsen J.K., Sørensen S.S., Hansen H.E., Pedersen E.B. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Nephrol. Dial. Transplant. 1998; 13(9): 2327-2334